ClinicalTrials.gg
RecruitingNCT07942753Updated Nov 17, 2026

Brain-Body Electrophysiology Using Stereoelectroencephalography

An observational study in Drug-Resistant Epilepsy and Brain-Body Physiological Coupling, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Xuanwu Hospital, Beijing · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
14 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.

Started
2026
the only one that year
Observational
3 of 15
2 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
15th of 15
by date

Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one is the only one that started in 2026, is one of 3 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 15th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 67 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 40 (60%) stop at 75 or younger; 26 take children under 18; 6 take healthy volunteers.

This study: 14 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This observational study aims to understand how electrical activity in the brain is related to activity in the stomach, heart, respiratory system, blood pressure, and glucose levels in people with drug-resistant epilepsy undergoing stereoelectroencephalography (SEEG) monitoring as part of their clinical care.

Researchers will collect synchronized recordings of brain activity and available body signals, including surface electrogastrography, electrocardiography and heart rate, abdominal respiratory movement, continuous glucose monitoring, and noninvasive blood pressure. The study will examine brain-body relationships during wakefulness, sleep, meals, seizures, and routine electrical stimulation or functional mapping performed for clinical purposes.

All decisions about SEEG implantation, electrical stimulation, functional mapping, medication, and other clinical care are made independently by the treating clinical team. The research protocol does not assign, add, or modify any electrical stimulation or treatment. The study only records and analyzes physiological responses associated with routine clinical care and naturally occurring physiological states.

03

Conditions studied

  • Drug-Resistant Epilepsy
  • Brain-Body Physiological Coupling

Keywords

  • Brain-Body Interactions
  • Stereoelectroencephalography
  • Respiration
  • Continuous Glucose Monitoring
04

Who can participate

Ages eligible
14 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients aged 14 to 60 years with drug-resistant epilepsy who are admitted to Xuanwu Hospital, Capital Medical University, for clinically indicated stereoelectroencephalography monitoring. Eligible patients will be enrolled prospectively during inpatient monitoring. Participants may contribute synchronized SEEG and available gastric, cardiac, respiratory-movement, blood pressure, and glucose data. Clinical treatment, electrode implantation, medication changes, seizure monitoring, and intracranial electrical stimulation or functional mapping are determined independently by the treating clinical team.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 14 to 60 years.
  • Diagnosis of drug-resistant epilepsy.
  • Selected by the clinical multidisciplinary team to undergo stereoelectroencephalography monitoring for clinical purposes.
  • Expected to provide analyzable data for at least one study module.
  • Able to understand the study procedures and requirements.
  • Written provided by an adult participant or legal guardian. Participants aged 14 to 17 years must also provide assent when appropriate.

Exclusion criteria

Exclusion Criteria:

  • or intolerance to the additional noninvasive physiological sensors used in the study.
  • Significant skin disease, infection, or injury that prevents safe placement of abdominal, electrocardiographic, continuous glucose monitoring, or blood pressure sensors.
  • Inability to obtain valid or assent.
  • Clinical judgment that research-related recording would materially interfere with necessary medical care.

Gastrectomy, gastric electrical stimulation devices, or established gastroparesis will not automatically exclude a participant from the overall cohort. These participants may contribute to other eligible study modules but will be excluded from the primary brain-stomach analysis or analyzed as a special physiology subgroup.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients Undergoing Clinically Indicated SEEG Monitoring

    Patients aged 14 to 60 years with drug-resistant epilepsy who undergo stereoelectroencephalography monitoring based on clinical indications. Synchronized brain and peripheral physiological signals are observed during natural physiological states, clinical seizures, and routine electrical stimulation or functional mapping. The study does not assign or modify SEEG implantation, electrical stimulation, medication, or other clinical care.

    Procedure: Clinically Indicated Stereoelectroencephalography Monitoring · Procedure: Clinically Indicated Intracranial Electrical Stimulation and Functional Mapping

Interventions

  • ProcedureClinically Indicated Stereoelectroencephalography Monitoring

    Participants undergo SEEG monitoring as part of routine clinical evaluation for drug-resistant epilepsy. The research study records and analyzes SEEG together with available gastric, cardiac, respiratory, blood pressure, and glucose signals. The decision to perform SEEG and the placement of electrodes are determined independently by the clinical care team.

  • ProcedureClinically Indicated Intracranial Electrical Stimulation and Functional Mapping

    Some participants may undergo intracranial electrical stimulation or functional mapping as part of routine clinical care. Stimulation targets, timing, parameters, and clinical indications are determined independently by the treating clinical team. The research protocol does not assign, add, or modify stimulation and only observes associated physiological responses.

06

What researchers measure

Primary outcomes

  1. Mean Heartbeat-Evoked SEEG Potential Amplitude at 200-500 Milliseconds After the ECG R Peak

    Heartbeat-evoked potentials will be measured from stereoelectroencephalography (SEEG) recordings time-locked to R peaks detected by simultaneous electrocardiography (ECG). The outcome is the mean signed potential amplitude from 200 to 500 milliseconds after the R peak, relative to the mean potential from 200 to 50 milliseconds before the R peak, expressed in microvolts (µV). Eligible heartbeats will be averaged within each segment and bipolar derivation. Derivations with prominent cardiac-field artifacts will be excluded. Results will be summarized by anatomical region and physiological state within each participant before cohort-level analysis. Pseudo-R-peak analyses will assess responses beyond chance.

    Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.

  2. Circular-Linear Correlation Coefficient Between ECG-Derived Cardiac Phase and SEEG Frequency-Band Amplitude

    Cardiac phase will be derived from successive R peaks detected by electrocardiography (ECG). Neural amplitude will be derived from the Hilbert envelope of bipolar stereoelectroencephalography (SEEG) recordings in delta (1-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz), low-gamma (30-70 Hz), and high-frequency (70-170 Hz) bands, excluding line-noise frequencies. Log-transformed amplitude will be regressed on sine and cosine of cardiac phase. The outcome is the multiple correlation coefficient R, calculated as the square root of explained variance (R²); it is dimensionless and ranges from 0 to 1. Higher values indicate stronger phase-dependent amplitude modulation. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Autocorrelation-preserving surrogates will assess coupling beyond chance.

    Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.

  3. Circular-Linear Correlation Coefficient Between Cutaneous EGG-Derived Gastric Phase and SEEG Frequency-Band Amplitude

    Gastric slow-wave phase will be obtained from cutaneous electrogastrography (EGG), recorded using abdominal surface electrodes connected to the SEEG acquisition system. An individually verified gastric peak within 2-4 cycles per minute will define phase extraction. SEEG frequency-band amplitude will be obtained from bipolar recordings in delta, theta, alpha, beta, low-gamma, and high-frequency bands. Log-transformed amplitude will be regressed on sine and cosine of gastric phase. The outcome is the multiple correlation coefficient R, calculated as the square root of R²; it is dimensionless and ranges from 0 to 1. Higher values indicate stronger coupling. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Autocorrelation-preserving surrogates will assess coupling beyond chance. Segments without a verified gastric rhythm will not contribute coupling estimates.

    Time frame: During 20-minute analysis segments in awake fasting, postprandial, and non-rapid eye movement sleep states, collected over 1-14 days of inpatient SEEG monitoring.

  4. Circular-Linear Correlation Coefficient Between Abdominal Respiratory-Movement Proxy Phase and SEEG Frequency-Band Amplitude

    Respiratory-movement proxy phase will be extracted from the 0.1-0.5 Hz component of abdominal surface-electrode signals recorded by the SEEG acquisition system. This is an abdominal-movement proxy, not an independent airflow or respiratory-belt measurement. SEEG frequency-band amplitude will be obtained from bipolar recordings in delta, theta, alpha, beta, low-gamma, and high-frequency bands. Log-transformed amplitude will be regressed on sine and cosine of respiratory-proxy phase. The outcome is the multiple correlation coefficient R, calculated as the square root of R²; it is dimensionless and ranges from 0 to 1. Higher values indicate stronger coupling. Results will be summarized by anatomical region, frequency band, and physiological state within each participant. Only segments with identifiable respiratory cycles will be analyzed; autocorrelation-preserving surrogates will assess coupling beyond chance.

    Time frame: During analysis segments lasting at least 5 minutes, collected over 1-14 days of inpatient SEEG monitoring.

  5. Change in Mean Arterial Pressure During the First 10 Minutes After Clinically Indicated Intracranial Electrical Stimulation

    Mean arterial pressure (MAP) will be measured in millimeters of mercury (mmHg) using a CNSystems noninvasive continuous beat-to-beat blood pressure monitor. The outcome is mean MAP during 0-10 minutes after stimulation ends minus mean MAP during the 10 minutes immediately before stimulation begins, expressed in mmHg. Only valid recorded beats will contribute to each interval mean. Exposure-level changes will be summarized within each participant and stimulation target before cohort-level analysis. Stimulation is performed solely for clinically indicated functional mapping or other clinical care; the research protocol does not assign or modify stimulation.

    Time frame: From 10 minutes before stimulation begins to 10 minutes after stimulation ends, within a recording window extending from 15 minutes before to 30 minutes after each exposure during inpatient SEEG monitoring.

  6. Cumulative 0-120-Minute Distributed-Lag Regression Coefficient for SEEG Frequency-Band Power and CGM-Measured Interstitial Glucose

    Interstitial glucose concentration will be measured in mmol/L using a MicroTech continuous glucose monitor (CGM) recording once per minute. Frequency-band power will be derived from bipolar stereoelectroencephalography (SEEG) in delta, theta, alpha, beta, low-gamma, and high-frequency bands. SEEG log power will be summarized in 5-minute bins and standardized within each participant; CGM values will be averaged in matching bins. A distributed-lag mixed model will relate earlier SEEG log power to glucose concentration at lags of 0-120 minutes. The outcome is the sum of lag-specific regression coefficients, expressed in mmol/L per 1-standard-deviation sustained increase in SEEG log power across the lag window. Results will be reported by anatomical region and frequency band. Models will account for participant baseline, time of day, sleep, meals, medication, seizures, and serial autocorrelation.

    Time frame: During 1-14 days of inpatient SEEG monitoring, using 5-minute analysis bins and SEEG-to-glucose lags of 0-120 minutes.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Nov 17, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942753
Responsible party
Liankun_Ren (Chief Physician and Principal Investigator, Department of Neurology, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Nov 17, 2026
Start date
Jul 29, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Liankun Ren
Contact
renlk2022@outlook.com
13681576621

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion